Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 52Ovarian Neoplasms 40Multiple Myeloma 20Fallopian Tube Neoplasms 13Lymphoma 12Sarcoma 11Carcinoma, Ovarian Epithelial 11Triple Negative Breast Neoplasms 8Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Neoplasms 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 6Neoplasms, Plasma Cell 5Sarcoma, Ewing 4Prostatic Neoplasms 4Neoplasm Metastasis 4Lymphoma, Mantle-Cell 4Burkitt Lymphoma 4Rhabdomyosarcoma 3Osteosarcoma 3Lymphoma, T-Cell, Peripheral 3Leiomyosarcoma 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Solid Tumors 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × liposomal doxorubicin × Clear all
NCT00949325 2019-03-11

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
24 enrolled 14 charts
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡